Yufeng Cheng1, Kai Wang2, Wei Ma3, Xiaomei Zhang4, Yipeng Song5, Jianbo Wang4, Nana Wang4, Qingxu Song4, Fangli Cao4, Bingxu Tan4, Jinming Yu6. 1. Tianjin Medical University Tianjin 300000, People's Republic of China ; Oncology Center, Qilu Hospital of Shandong University 107 West Wenhua Road, Jinan 250012, People's Republic of China. 2. Oncology Center, Qilu Hospital of Shandong University (Qingdao) 758 Hefei Road, Qingdao 266035, People's Republic of China. 3. General Hospital of Ningxia Medical University Yinchuan 750004, People's Republic of China. 4. Oncology Center, Qilu Hospital of Shandong University 107 West Wenhua Road, Jinan 250012, People's Republic of China. 5. Department of Oncology, Yantai Yuhuangding Hospital Yantai 264000, People's Republic of China. 6. Tianjin Medical University Tianjin 300000, People's Republic of China.
Abstract
OBJECTIVE: Cancer-associated fibroblasts (CAFs; α-SMA positivity), as a representative of the tumor microenvironment, play an important role in influencing the proliferation, invasion and metastasis of cancer cells. The objective is to investigate the prognostic value of CAFs density in esophageal squamous cell carcinoma (ESCC) after surgery. METHOD: A total of 95 patients who underwent esophagectomy for ESCC in 2007 were included in this study. These specimens were immunostained with α-smooth muscle actin (α-SMA) antibodies to quantify CAFs. Antibodies D2-40 and CD34 were used to evaluate the lymphatic vessel density (LVD) and microvessel density (MVD) of the lesions. The Cox proportional hazards model was used to determine the hazard ratio of CAFs density on 3-year overall survival and 3-year disease-free survival. The correlation between CAFs density and lymphatic vessel density (LVD) or microvessel density (MVD) were analyzed. RESULTS: 3-year overall survival rate in the CAF-poor group (63%) was significantly better than those in the CAF-rich group (42%) (P < 0.01). In the Cox univariate and multivariate analysis of 3-year overall survival, the hazard ratio (HR) of CAFs density was 1.870 (95% CI 1.033-3.385; P = 0.039) and 2.196 (95% CI 1.150-4.193; P = 0.017), respectively. CAFs density was proved to be an independent prognostic factor for 3-year overall survival. CAFs density correlated significantly with increased LVD and MVD in ESCC. CONCLUSION: CAFs density may be a marker for predicting prognosis and guiding therapeutic management of ESCC.
OBJECTIVE: Cancer-associated fibroblasts (CAFs; α-SMA positivity), as a representative of the tumor microenvironment, play an important role in influencing the proliferation, invasion and metastasis of cancer cells. The objective is to investigate the prognostic value of CAFs density in esophageal squamous cell carcinoma (ESCC) after surgery. METHOD: A total of 95 patients who underwent esophagectomy for ESCC in 2007 were included in this study. These specimens were immunostained with α-smooth muscle actin (α-SMA) antibodies to quantify CAFs. Antibodies D2-40 and CD34 were used to evaluate the lymphatic vessel density (LVD) and microvessel density (MVD) of the lesions. The Cox proportional hazards model was used to determine the hazard ratio of CAFs density on 3-year overall survival and 3-year disease-free survival. The correlation between CAFs density and lymphatic vessel density (LVD) or microvessel density (MVD) were analyzed. RESULTS: 3-year overall survival rate in the CAF-poor group (63%) was significantly better than those in the CAF-rich group (42%) (P < 0.01). In the Cox univariate and multivariate analysis of 3-year overall survival, the hazard ratio (HR) of CAFs density was 1.870 (95% CI 1.033-3.385; P = 0.039) and 2.196 (95% CI 1.150-4.193; P = 0.017), respectively. CAFs density was proved to be an independent prognostic factor for 3-year overall survival. CAFs density correlated significantly with increased LVD and MVD in ESCC. CONCLUSION: CAFs density may be a marker for predicting prognosis and guiding therapeutic management of ESCC.
Authors: M G Kellermann; L M Sobral; S D da Silva; K G Zecchin; E Graner; M A Lopes; I Nishimoto; L P Kowalski; R D Coletta Journal: Histopathology Date: 2007-12 Impact factor: 5.087
Authors: Ibrahim O Bello; Marilena Vered; Dan Dayan; Alex Dobriyan; Ran Yahalom; Kalle Alanen; Pentti Nieminen; Saara Kantola; Esa Läärä; Tuula Salo Journal: Oral Oncol Date: 2010-11-26 Impact factor: 5.337
Authors: Eric Smith; Helen M Palethorpe; Annette L Hayden; Joanne P Young; Timothy J Underwood; Paul A Drew Journal: Sci Rep Date: 2017-06-13 Impact factor: 4.379